Abstract

The present invention describes a composition comprising carbon dots, which are luminescent, biocompatible, water-soluble carbon nanoparticles that can be obtained from carbohydrates. The invention also provides a method of preparing said composition and use of said composition to increase the productivity of a vegetable crop by using abundant and easily accessible raw materials, via a low-cost method and on a large scale.

IPC Classes  ?

• C01B 32/15 - Nanosized carbon materials
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C05F 11/00 - Other organic fertilisers

Abstract

The present invention relates to a method for predicting herd animal body mass which comprises the following steps: collecting data from the livestock environment; detecting and selecting the animal; determining geometric features of each RGB-D depth image; and obtaining the herd animal body mass prediction. In addition, the present invention relates to a system for predicting herd body mass, comprising: at least one RGB-D capture assembly including at least one RGB-D imaging sensor; at least one storage module; and at least one remote monitoring module; wherein the storage module stores a set of instructions which, when executed by a processor, performs the method for predicting herd animal body mass.

IPC Classes  ?

• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
• G01G 17/08 - Apparatus for, or methods of, weighing material of special form or property for weighing livestock

Abstract

The present invention aims to provide a process for preparing a thermoplastic composite from cellulose pulp modified with waxes, or with polymer emulsions, and a thermoplastic composite prepared by means of both of said processes. The process is used to modify cellulose in the form of chemical pulp, microfibrillated cellulose (MFC) or nanofibrillated cellulose (NFC) by means of extrusion with waxes, or with a polymer emulsion, for subsequent use of the product obtained as a reinforcement in composites with thermoplastic resin.

IPC Classes  ?

• C08L 97/02 - Lignocellulosic material, e.g. wood, straw or bagasse
• C08L 1/14 - Mixed esters, e.g. cellulose acetate-butyrate
• C08F 210/06 - Propene
• C09J 123/10 - Homopolymers or copolymers of propene
• C08J 5/04 - Reinforcing macromolecular compounds with loose or coherent fibrous material
• B29C 48/00 - Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired formApparatus therefor

Abstract

The present invention aims to provide a process for preparing a thermoplastic composite from cellulose pulp modified by reactive extrusion with anhydrides, and a thermoplastic composite prepared by means of said process. The process is used to modify cellulose in the form of chemical pulp, microfibrillated cellulose (MFC) or nanofibrillated cellulose (NFC) by means of reactive extrusion (REX) in the presence of an aprotic solvent with the ability to swell the cellulose, for subsequent use of the product obtained as a reinforcement in composites with thermoplastic resin.

IPC Classes  ?

• C08F 255/02 - Macromolecular compounds obtained by polymerising monomers on to polymers of hydrocarbons as defined in group on to polymers of olefins having two or three carbon atoms
• C08F 4/34 - Per-compounds with one peroxy-radical
• C08L 23/12 - Polypropene
• C08L 51/02 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers grafted on to polysaccharides
• C08L 51/06 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers grafted on to homopolymers or copolymers of aliphatic hydrocarbons containing only one carbon-to-carbon double bond
• C08L 97/02 - Lignocellulosic material, e.g. wood, straw or bagasse
• B29C 48/02 - Small extruding apparatus, e.g. handheld, toy or laboratory extruders
• C08L 23/26 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bondCompositions of derivatives of such polymers modified by chemical after-treatment
• C08J 5/04 - Reinforcing macromolecular compounds with loose or coherent fibrous material

Abstract

The present invention is a new route for recycling batteries used in the electrical and electronic equipment sector and in the automotive sector. This invention encompasses batteries of different types of active cathode materials, such as LCO (LiCoO2), NCA (LiNiCOAlO2), LMO (LiMnO2 or LiMn2O4), NMC (LiNixMnyCozO2), and LMO-NMC (LiNiCoAlO2-LiNixMnyCozO2)) of prismatic, cylindrical and pouch types. The process involves the following steps: discharging the batteries, dismantling and separating the battery components, grinding the battery cells, precipitating fluorine and lithium, leaching with acid, separating the manganese by ozonation, precipitating aluminum, extracting cobalt by solvents, precipitating nickel and precipitating the remaining lithium. The present invention includes an acid leaching step without the use of a reducing agent, which can achieve values close to 99 percent efficiency for Ni, Co, Mn and Li, and mechanical processing without any heat treatment to concentrate the metals of interest in the battery cathodes. The present invention also relates to a lithium-ion battery recycling process that uses a metal separation route by ozonation followed by electrodialysis, as well as a lithium-ion battery recycling process that uses a metal separation route by electrodialysis.

IPC Classes  ?

• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 26/12 - Obtaining lithium
• C22B 1/00 - Preliminary treatment of ores or scrap

Abstract

224z22), and LMO-NMC with prismatic, cylindrical and pouch cells. The process has steps of: discharging the batteries, disassembling and separating the components of the battery, grinding the battery cells, precipitating the fluoride and lithium, leaching with acid, separating the manganese via ozonation, precipitating aluminum, extracting cobalt via solvents, precipitating nickel and precipitating the remaining lithium. The present invention has a step of acid leaching without the use of a reducing agent, which can reach near-99% efficiency for Ni, Co, Mn and Li, and mechanical processing with no heat treatment to concentrate the metals of interest from the battery cathodes.

IPC Classes  ?

• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 26/12 - Obtaining lithium
• C22B 1/00 - Preliminary treatment of ores or scrap

Abstract

The present invention relates to a nanostructured aqueous formulation containing a high content of propolis extract, in particular Brazilian green or red propolis extract, intended for use in pharmaceutical, food, cosmetic and veterinary formulations. The bioactives present in the propolis extract are responsible for the antioxidant, anti-inflammatory, anti-tumour and antiviral activities thereof, which are enhanced and protected by the encapsulation of the extract in the lipid nanostructure.

IPC Classes  ?

• A61K 35/644 - BeeswaxPropolisRoyal jellyHoney
• A61K 9/10 - DispersionsEmulsions
• A61K 9/51 - Nanocapsules
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

A kit is disclosed, for the destruction of cancer cells with stem cell properties based on the oncolytic action of the Zika virus, associated with the aggressiveness of malignant tumors and an unfavorable clinical prognosis, especially in malignant tumors of the nervous system. The kit contains a pharmaceutical composition, sterile glass vials with a rubber seal, and syringes with sterile and disposable needles for injection.

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

This invention relates to an ore beneficiation process by flotation. In this context, an ore beneficiation system is provided with application of ultrasound to the flotation froth comprising an air-emission ultrasonic transducer positioned above the flotation froth, with the ultrasonic transducer being adapted to emit ultrasonic waves towards the flotation froth. This invention also provides an ore beneficiation process associated with the system described above. Thus, this invention provides a process and system for ore beneficiation with the application of ultrasound to the flotation froth without immersing the ultrasonic transducer into the ore slurry. The current invention can partially remove the liquid film that resides between the air bubbles, thereby enhancing metallurgical recovery rates. Furthermore, it can be employed to effectively counteract the persistence of three-phase froth resulting from flotation, thereby improving the efficiency of processes associated with water and waste management.

IPC Classes  ?

• B03D 1/02 - Froth-flotation processes
• B03D 1/18 - Flotation machines with impellersSubaeration machines without air supply
• B06B 1/00 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency

Abstract

Disclosed is a method for producing hybrid or non-hybrid recombinant glycoprotein hormones, for example the recombinant equine chorionic gonadotropin (r-eCG), the hybrid recombinant chorionic gonadotropin, the recombinant thyroid-stimulating hormone (r-TSH), the recombinant luteinizing hormone (r-LH), the luteinizing hormone and the recombinant follicle-stimulating hormone (r-FSH). In addition, the present disclosure relates to the recombinant glycoprotein hormones comprising the equine α and β subunits, inter alia, the α subunit of mammals and equine β subunit, where the two subunits are fused in a simple chain, and chain-modifying agents, which hormones are easier to purify, more homogeneous, easier to produce on an industrial scale without using animals, in comparison with the wild glycoprotein hormone. The hormones are useful for inducing animal reproduction, ovulation induction, superovulation induction, follicle growth, estrus induction, anoestrus reversal, puberty induction in animals, both with and without commercial interest.

IPC Classes  ?

• C07K 14/59 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. hCG [human chorionic gonadotropin]Luteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis

Abstract

The present invention relates to a functionalized cellulose in which the cellulose comprises hydrophobic ester groups from fatty acids, and also to processes and methods for functionalizing cellulose that produce cellulose with increased hydrophobicity.

IPC Classes  ?

• C08B 3/10 - Preparation of cellulose esters of organic acids of monobasic organic acids with three or more carbon atoms with five or more carbon atoms
• C08B 3/20 - Esterification with maintenance of the fibrous structure of the cellulose
• C12P 7/62 - Carboxylic acid esters
• D21C 5/00 - Other processes for obtaining cellulose, e.g. cooking cotton linters

Abstract

The present invention describes nanostructured lipid systems containing the antibiotic besifloxacin and the application thereof in the treatment and prevention of bacterial eye infections. Besifloxacin, an antibiotic with low aqueous solubility, is encapsulated in a nanostructured lipid system comprising a solid lipid, a liquid lipid, a surfactant and a co-surfactant. Optionally, the system of the invention can be additionally coated with an antibacterial cationic agent. The nanostructured lipid system according to the invention allows the topical administration of besifloxacin in the eyes and gives the drug a longer retention time on the surface of the eye. Furthermore, the system described herein is designed using industrially applicable methods and remains stable under storage conditions for at least 90 days, so it can be readily reproduced on an industrial scale.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 9/51 - Nanocapsules
• A61K 9/107 - Emulsions
• A61K 38/12 - Cyclic peptides
• A61P 27/02 - Ophthalmic agents
• A61P 31/02 - Local antiseptics
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to tetracycline derivatives and their use as a medicament, in particular in treatment or prevention of a disease selected from the group comprising or consisting of: amyloidosis, pain, neurodegenerative diseases and neuroinflammatory diseases.

IPC Classes  ?

• C07C 235/82 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A polypropylene fiber including: a polypropylene matrix, at least a surface modifier, and at least an additive selected from surfactants, lubricating agents or mixtures thereof. A method of producing polypropylene fibers by (i) mixing a polypropylene with a surface modifier in extrusion, (ii) melt spinning the composition obtained in step (i) to produce the fibers, where a surfactant is added to step (i) and/or a lubricant is applied to the fibers during step (ii). A fiber cement-reinforced composite including a cementitious matrix, a cellulosic component, optionally, a limestone component and a polypropylene fiber comprising: a polypropylene matrix, at least a surface modifier, at least one additive selected from surfactants, lubricating agents and mixtures thereof. An article comprising the fiber cement-reinforced composite and a roof tile comprising the fiber cement-reinforced composite.

IPC Classes  ?

• D01F 6/06 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polyolefins from polypropylene
• D01F 1/10 - Other agents for modifying properties
• D01F 6/46 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from mixtures of polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds as major constituent with other polymers or low-molecular-weight compounds of polyolefins
• E04C 5/07 - Reinforcing elements of material other than metal, e.g. of glass, of plastics, or not exclusively made of metal

Abstract

A polypropylene fiber including: a polypropylene matrix, at least a surface modifier, and at least an additive selected from surfactants, lubricating agents or mixtures thereof. A method of producing polypropylene fibers by (i) mixing a polypropylene with a surface modifier in extrusion, (ii) melt spinning the composition obtained in step (i) to produce the fibers, where a surfactant is added to step (i) and/or a lubricant is applied to the fibers during step (ii). A fiber cement-reinforced composite including a cementitious matrix, a cellulosic component, optionally, a limestone component and a polypropylene fiber comprising: a polypropylene matrix, at least a surface modifier, at least one additive selected from surfactants, lubricating agents and mixtures thereof. An article comprising the fiber cement-reinforced composite and a roof tile comprising the fiber cement-reinforced composite.

IPC Classes  ?

• C04B 16/06 - Macromolecular compounds fibrous
• C04B 28/04 - Portland cements
• D01F 6/06 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polyolefins from polypropylene
• D01F 1/10 - Other agents for modifying properties

Abstract

The present invention provides a biosensor system comprising one or more electrodes capable of converting a physicochemical signal transduced from a biorecognition layer into an electronic signal; a biorecognition layer comprising biomolecules immobilized onto one or more electrodes capable of binding to the specific analyte of the nematode species as well as a method for detecting simultaneously more than one nematode species.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The present disclosure relates to the field of building materials. In particular, the present disclosure relates to fiber cement production methods and processes that exhibit high solid retention capacity in the dewatering step, providing increased productivity and potentially other process gains related to the lower concentration of solids and additives in the process water.

IPC Classes  ?

• C04B 7/02 - Portland cement

Abstract

in vitro in vitroin vitro methods and kit for predicting the risk of developing Post-Chikungunya Chronic Inflammatory Joint Disease (pCHIKV-CIJD) in a subject. The method comprises a step of evaluating the expression of one or more biomarkers in a biological sample obtained from said subject, for example a blood sample, wherein said one or more biomarkers are selected among specific long non-coding RNAs, and wherein a higher expression than control expression value indicates a risk of developing pCHIKV-CIJD.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to a process for extracting proteins from malt bagasse, said process comprising the steps of: (a) drying and grinding the malt bagasse; (b) mixing the malt bagasse obtained in step (a) with a solution comprising a mixture of an alkali metal salt or an alkaline earth metal salt with an alkaline solution in a concentration of up to 0.5 M; (c) subjecting the bagasse to extraction with stirring; (d) extracting the supernatant by means of solid/liquid separation; (e) adjusting the pH of the extracted supernatant using an HCl solution in a concentration of up to 2 M; (f) performing a solid/liquid separation; and (g) washing the precipitated concentrate using alcohol. Optionally, in addition, the process also comprises the step (h) of solubilising the protein extract by increasing the pH using NaOH in a concentration of up to 1.0 M, under constant stirring, until a pH of between 6.0 and 8.0 is reached, and then cooling same. The present invention also relates to the food product comprising the protein obtained by means of the process described according to the invention, and also to the use of the protein extracted by the process in order to increase the protein content of a food product or to substitute the use of proteins from other sources.

IPC Classes  ?

• A23J 1/16 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from waste water of starch-manufacturing plant or like wastes

Abstract

The present invention relates to a method for ore processing by flotation. Within this context, an ore processing system is provided with the application of ultrasound to the flotation froth, comprising an ultrasonic transducer (10) for transmission in air positioned above the flotation froth, the ultrasonic transducer (10) being capable of transmitting ultrasonic waves towards the flotation froth. The present invention further provides an ore processing method associated with the system described above. The present invention therefore provides a method and a system for processing ore with the application of ultrasound to the flotation froth without submerging the ultrasonic transducer (10) in the ore pulp. The present invention is capable of partially draining the liquid film existing between the air bubbles, promoting increased metallurgical recovery, and can also be used to eliminate persistent three-phase froths generated by flotation, improving the efficiency of the methods involved in water and waste management.

IPC Classes  ?

• B03D 1/02 - Froth-flotation processes
• B03D 1/14 - Flotation machines
• B06B 1/00 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency

Abstract

The present invention relates to a functionalized cellulose, in which the cellulose comprises hydrophobic ester groups from fatty acids, and also to processes and methods for functionalizing cellulose that produce cellulose with increased hydrophobicity.

IPC Classes  ?

• C08B 15/00 - Preparation of other cellulose derivatives or modified cellulose
• C08H 8/00 - Macromolecular compounds derived from lignocellulosic materials
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C07C 67/02 - Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
• C12N 11/14 - Enzymes or microbial cells immobilised on or in an inorganic carrier
• C12P 7/62 - Carboxylic acid esters
• D21C 3/20 - Pulping cellulose-containing materials with organic solvents

Abstract

The present invention relates to a functionalized cellulose, in which the cellulose comprises hydrophobic ester groups from fatty acids, and also to processes and methods for functionalizing cellulose that produce cellulose with increased hydrophobicity.

IPC Classes  ?

• C08B 15/00 - Preparation of other cellulose derivatives or modified cellulose
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
• C12N 11/14 - Enzymes or microbial cells immobilised on or in an inorganic carrier
• C12P 7/62 - Carboxylic acid esters
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C08H 8/00 - Macromolecular compounds derived from lignocellulosic materials
• D21C 3/20 - Pulping cellulose-containing materials with organic solvents
• C07C 67/02 - Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification

Abstract

The present invention describes methods for obtaining functionalized polymeric surfaces (MPn-PSm) from polymers or copolymers with appropriate functionalizations (X), which can be a halogen of a leaving group, such as polyvinyl chloride (MP1) and (chloromethyl)polystyrene-Merrifield (MP2), and curcumin photosensitizers (PS1), meso-tetra(aryl)porphyrins, chlorins or bacteriochlorins halogenated and functionalized with nucleophilic groups (PS2), in particular including P2 of the type meso-imidazoyl-porphyrins, chlorins or bacteriochlorins (PS3). The structures of all the photosensitizers in the present application incorporate a functional group (Y), which is a OH, SH or NH2nucleophile. The application also describes the covalent bonding process of the photosensitizers PS1-PS3 to the functional polymeric materials MP1-MP2 by means of a nucleophilic substitution reaction to prepare the MPn-Psm products. The formed products prevent microbial proliferation, which can cause the serious infections that are one of the main causes of death in patients using these devices.

IPC Classes  ?

• C08C 19/44 - Addition of a reagent which reacts with a hetero atom or a group containing hetero atoms of the macromolecule reacting with metals or metal-containing groups of polymers containing metal atoms exclusively at one or both ends of the skeleton
• C08C 19/25 - Incorporating silicon atoms into the molecule
• C08F 8/14 - Esterification

Abstract

The present invention describes a solid pharmaceutical composition including an external coating containing immediate-release vitamin D, and a matrix containing prolonged-release vitamin D and calcium salt, having the technical effect of improving calcium absorption, since it enables suitable concentrations of vitamin D in the blood throughout the release of calcium, which reduces the quantity of calcium excreted in faeces and improves the effectiveness of treatments for osteoporosis and other illnesses related to inadequate concentrations of calcium in the blood. The composition of the present invention can also be provided as mini-pills to facilitate administration by mouth, and also to modulate the quantity of calcium and vitamin D consumed by the patient/user. The present invention describes a solid pharmaceutical composition, a method for treating or preventing conditions related to low ingestion of and/or higher need for calcium, use of the solid pharmaceutical composition, and a pharmaceutical product or supplement. The present invention pertains to the field of medical preparations containing organic and inorganic active substances.

IPC Classes  ?

• A61K 36/04 - Rhodophycota or rhodophyta (red algae), e.g. Porphyra
• A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 33/10 - CarbonatesBicarbonates
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/22 - Sustained or differential release type
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

in vitroOnchocerca lupiin vitroOnchocerca lupiOnchocerca lupi infection.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure pertains to the field of building materials. In particular, the present disclosure relates to methods and processes for producing fiber cements that have high solid retention capacity in the drying stage, increasing productivity and potentially providing other process gains related to the lower concentration of solids and additives in the process water.

IPC Classes  ?

• C04B 16/06 - Macromolecular compounds fibrous
• B01D 21/00 - Separation of suspended solid particles from liquids by sedimentation
• C04B 14/00 - Use of inorganic materials as fillers, e.g. pigments, for mortars, concrete or artificial stoneTreatment of inorganic materials specially adapted to enhance their filling properties in mortars, concrete or artificial stone

Abstract

The present disclosure pertains to the field of building materials. In particular, the present disclosure relates to methods and processes for producing fiber cements that have high solid retention capacity in the drying stage, increasing productivity and potentially providing other process gains related to the lower concentration of solids and additives in the process water.

IPC Classes  ?

• C04B 16/06 - Macromolecular compounds fibrous
• C04B 14/00 - Use of inorganic materials as fillers, e.g. pigments, for mortars, concrete or artificial stoneTreatment of inorganic materials specially adapted to enhance their filling properties in mortars, concrete or artificial stone
• B01D 21/00 - Separation of suspended solid particles from liquids by sedimentation

Abstract

The present invention describes MRI contrast agents based on amorphous diamagnetic metal oxide nanoparticles with bound paramagnetic metal ions on the surface thereof, that form nanofluids in aqueous media, combined with molecules, biomolecules, bioactive molecules, derivatives of polymers and biopolymers, and that are used as T1 and T2 contrast agents suitable for the effective and safe diagnosis of illnesses. The present invention pertains to the fields of chemistry and nanotechnology applied to medicine, and more specifically to contrast agents for magnetic resonance imaging diagnosis.

IPC Classes  ?

• A61K 49/06 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations
• A61K 33/24 - Heavy metalsCompounds thereof
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 9/51 - Nanocapsules
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention describes methods for obtaining functionalized polymeric surfaces (MPn-PSm) from polymers or copolymers with appropriate functionalizations (X), which can be a halogen of a leaving group, such as polyvinyl chloride (MP1) and (chloromethyl)polystyrene-Merrifield (MP2), and curcumin photosensitizers (PS1), meso-tetra(aryl)porphyrins, chlorins or bacteriochlorins halogenated and functionalized with nucleophilic groups (PS2), in particular including P2 of the type meso-imidazoyl-porphyrins, chlorins or bacteriochlorins (PS3). The structures of all the photosensitizers in the present application incorporate a functional group (Y), which is a OH, SH or NH 2nucleophile. The application also describes the covalent bonding process of the photosensitizers PS1-PS3 to the functional polymeric materials MP1-MP2 by means of a nucleophilic substitution reaction to prepare the MPn-Psm products. The formed products prevent microbial proliferation, which can cause the serious infections that are one of the main causes of death in patients using these devices.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61K 31/12 - Ketones
• A61K 31/33 - Heterocyclic compounds
• A61L 29/04 - Macromolecular materials
• A61L 29/16 - Biologically active materials, e.g. therapeutic substances

Abstract

meso22 nucleophile. The application also describes the covalent bonding process of the photosensitizers PS1-PS3 to the functionalized polymeric materials MP1-MP2 by means of a nucleophilic substitution reaction to prepare the MPn-PSm products. The formed products prevent microbial proliferation, which can cause the serious infections that are one of the main causes of death in patients using these devices.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61L 29/04 - Macromolecular materials
• A61L 29/16 - Biologically active materials, e.g. therapeutic substances
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61K 31/33 - Heterocyclic compounds
• A61K 31/12 - Ketones

Abstract

A pharmaceutical composition containing synthetic Cannabidiol and its use in obtaining a medication for the treatment of neurological disorders, as well as the main excipients used in the production process, in addition to its small, medium, and large-scale preparation process. The use of the composition for the treatment of neurological disorders in human or animal populations, in particular in the treatment of Parkinson's disease, in the range of 300 to 850 mg/day or at daily doses of 100 to 1750 mg for neuroprotective action.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to the production of a biologically active recombinant equine chorionic gonadotropin (reCG), to a veterinary composition comprising the reCG, and to the use of the reCG or of the composition comprising reCG. The reCG of the present invention has a glycosylation profile similar to that of commercially available chorionic gonadotropins and exhibits an in vivo activity level corresponding to that of eCG and similar to that of the hormones FSH and LH. The present invention is applicable in the field of biotechnology, and more specifically in the field of veterinary assisted reproduction, being especially suitable for use in treating veterinary conditions related to reproduction and ovulation in mammals, and also for manufacturing diagnostic kits or as a cell culture supplement.

IPC Classes  ?

• C07K 14/59 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. hCG [human chorionic gonadotropin]Luteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• A61K 38/24 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. HCGLuteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• C12N 15/16 - Hormones
• C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
• A61P 5/34 - Gestagens

Abstract

Disclosed are apparatuses and methods for irradiating a perfusate. The apparatus includes a tank which defines a first chamber. A separator is located inside the first chamber. The separator defines a second chamber. The first chamber and the second chamber are concentric and have substantially annular cross sections, each having at least one diameter and a substantially common longitudinal axis. A perfusate is introduced into the first chamber by an inlet. A UV radiation-emitting device is disposed inside the second chamber for providing irradiation to the perfusate. Irradiated perfusate is removed from the tank by an outlet. Other apparatuses and systems are described and methods for inactivating micro organisms by performing EVP and irradiating the perfusate.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• A61B 17/00 - Surgical instruments, devices or methods
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
• A61L 2/10 - Ultraviolet radiation
• A61L 2/24 - Apparatus using programmed or automatic operation
• A61L 2/26 - Accessories

Abstract

The present invention relates to the more efficient use of concrete in order to mitigate CO2 emissions from the concrete/cement chain. The present invention discloses a mixture of fines, comprising a Portland cement and a first filler or a second filler or a mixture thereof. The Portland cement comprises a proportion of 50-90% of the mixture, preferably of 60-80%, and more preferably still, the proportion of Portland cement in the mixture is 65-75%. One or both of the fillers comprise a proportion of 10-50% of the mixture, said proportion preferably being 20-40%, and more preferably still, the proportion of one or both of the fillers in the mixture is 25-35%. The filler of the present invention is an inorganic material obtained by grinding or particle-size sorting the raw material thereof. The first filler has a BET surface area of less than or equal to 6 m2/g and particle-size distribution with an average area defined by the range 4 µm < d98 < 40 µm, and a second filler has a BET surface area of less than or equal to 2.3 m2/g and particle size distribution of average area of 6 µm < d85 < 40 µm. The packing porosity of the mixture is at least 0.5 percent less than the packing porosity of the Portland cement used in the present mixture. The present invention also relates to concrete prepared from said mixture, the process for preparing said mixture and said concrete.

IPC Classes  ?

• C04B 14/04 - Silica-rich materialsSilicates
• C04B 14/22 - Glass
• C04B 14/36 - Inorganic materials not provided for in groups
• C04B 18/04 - Waste materialsRefuse
• C04B 7/02 - Portland cement
• C04B 7/13 - Mixtures thereof with inorganic cementitious materials, e.g. Portland cements
• C04B 7/19 - Portland cements
• C04B 7/26 - Cements from oil shales, residues or waste other than slag from raw materials containing flue dust
• C04B 7/28 - Cements from oil shales, residues or waste other than slag from combustion residues

Abstract

Aircraft wings and aircraft comprising the same include at least one high-lift system(e.g., a high-lift flap) and an aerodynamic seal associated operatively with the high-lift system, the aerodynamic seal includes a non-planra angulated plate structure which has an outwardly extended planr section having a proximal edge joined to the at least one high-lift flap at the outboard and/or inboard ends thereof, and a downwardly extended planar section joined at an angle to a terminal edge of the outwardly extended planar section.

IPC Classes  ?

• B64C 21/02 - Influencing air flow over aircraft surfaces by affecting boundary layer flow by use of slot, ducts, porous areas or the like

Abstract

The invention relates to a kit for destroying, on the basis of the oncolytic action of the Zika virus, cancerous cells with stem cell properties associated with malignant tumour aggressiveness and unfavourable clinical prognosis, especially in malignant tumours of the nervous system. Said kit comprises a pharmaceutical composition, sterile glass ampoules with a rubber seal, and syringes with sterile and disposable needles for injection.

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention describes a pharmaceutical composition containing synthetic cannabidiol and the use thereof in obtaining a medicinal product for the treatment of neurological disorders, and also the principal excipients used in the production process, in addition to the process for preparing same on a small, medium and large scale. More specifically, the present invention discloses the use of the composition for the treatment of neurological disorders in the human or animal population, especially in the treatment of Parkinson's disease, in a range of from 300 to 850 mg/day or in daily doses of 100 to 1750 mg for a neuroprotective action. The present invention pertains to the field of pharmacy and medicine.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention describes a pharmaceutical composition containing synthetic cannabidiol and the use thereof in obtaining a medicinal product for the treatment of neurological disorders, and also the principal excipients used in the production process, in addition to the process for preparing same on a small, medium and large scale. More specifically, the present invention discloses the use of the composition for the treatment of neurological disorders in the human or animal population, especially in the treatment of Parkinson's disease, in a range of from 300 to 850 mg/day or in daily doses of 100 to 1750 mg for a neuroprotective action. The present invention pertains to the field of pharmacy and medicine.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a dressing apparatus (100) for dressing a grinding wheel (10) and a method for dressing the grinding wheel (10) with such a dressing apparatus (100), whereas the dressing apparatus (100) comprises a dressing disc (11), which dressing disc (11) is configured to interact with the grinding wheel (10) in order to perform a dressing operation of the grinding wheel (10), and whereas the dressing apparatus comprises a spindle unit (12) for rotating the dressing disc (11). According to the invention, the dressing apparatus (100) further comprises an oscillation generator (13) to cause an oscillation movement in the dressing disc (11) while dressing the grinding wheel (10).

IPC Classes  ?

• B24B 53/053 - Devices or means for dressing or conditioning abrasive surfaces of cylindrical or conical surfaces on abrasive tools or wheels using a rotary dressing tool
• B24B 53/06 - Devices or means for dressing or conditioning abrasive surfaces of profiled abrasive wheels
• B24B 1/04 - Processes of grinding or polishingUse of auxiliary equipment in connection with such processes subjecting the grinding or polishing tools, the abrading or polishing medium or work to vibration, e.g. grinding with ultrasonic frequency

Abstract

A method for computing a shared key (K) for encrypting data between a first device and a second device. The method includes communicating a first private ephemeral key (XA), and a first parameter set (YA) to a second device. The first parameter set (YA) includes identity data (IDA) that identifies the first device, a random point (VA) on an elliptic curve, and a first public key (UA). The first device receives a second private ephemeral key (XB) and a second parameter set (YB). The second parameter set (YB) includes identity data (IDB) that identifies the second device, a random point (VB) on the elliptic curve, and a second public key (UB). Verifying operations are performed to verify the second public key (UB) and the second private ephemeral key (XB) as valid. A shared key (K) is then computed based at least on the first parameter set (YA), the second parameter set (YB), the first private ephemeral key (XA), and the second private ephemeral key (XB).

IPC Classes  ?

• H04L 9/08 - Key distribution
• H04L 9/30 - Public key, i.e. encryption algorithm being computationally infeasible to invert and users' encryption keys not requiring secrecy
• G06F 21/60 - Protecting data
• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules

Abstract

The present invention relates to a method for obtaining nanostructured lipid carriers comprising buparvaquone coated with cationic and anionic polymers associated with a polypeptide using high-pressure homogenisation technology to promote electrostatic interaction between the components thereof in an aqueous medium. The present invention also relates to the aforementioned nanostructured lipid carriers obtained, which comprise 0.5 to 50% w/v oil phase, 1 to 10% w/v surfactant, 50 to 500,000 IU/ml of a polypeptide, 0.01 to 2% w/v of a cationic polymer; 0.04 to 5% w/v of an anionic polymer, and purified water QSP, thereby enabling site-specific release in macrophages, enabling the development of innovative medicines to improve the treatment of leishmaniasis.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 9/107 - Emulsions
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

IPC Classes  ?

• A61L 2/08 - Radiation

Abstract

The present invention relates to a method for obtaining nanostructured amphiphilic cationic lipid and amphiphilic cationic polymer compounds that can contain at least two pharmaceutical drugs, a hydrophobic and a hydrophilic drug, associated with an oil phase and an aqueous phase, and coated with chitosan. The method comprises four steps which allow the nanostructures to be obtained in a controlled manner. Thus, it is possible to produce a cationic nanoparticle in a controlled manner. The present invention also relates to the thus obtained compounds and to the use thereof for developing pharmaceutical or cosmetic products in which the cationic nature is desirable, preferably ophthalmic products.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/10 - DispersionsEmulsions
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 38/12 - Cyclic peptides
• A61K 31/722 - ChitinChitosan
• A61P 31/04 - Antibacterial agents
• A61P 27/02 - Ophthalmic agents
• A61P 27/14 - Decongestants or antiallergics

Abstract

The present invention patent application relates to a novel process for producing carboxy metallo-phthalocyanines that can be used for producing dyes and pigments for the textile industry, inter alia, which is more efficient in producing said molecule, with a lower cost and an extremely low waste production level; the process in question comprises five steps, wherein the first step is that of a cyclization reaction and formation of the intermediate iron tetraimidophthalocyanine (TI-FePc) with a yield of approximately 35%; the second step is that of purifying the insoluble TI-FePc using a solution of HCl recovered in the fifth step; the third step is the step of a basic hydrolysis reaction using the solution recovered in the fourth step, generating the intermediate iron octacarboxyphthalocyanine (OC-FePc); the fourth step is the step of precipitating with calcium ions, separating the CaOC-FePc pigment and recovering the NaOH solution reused in the third step; and the fifth step is the step of acidification using hydrochloric acid and conversion of CaOC-FePc into the product HOC-FePc and recovery of the acid solution for reuse in the second and fifth steps.

IPC Classes  ?

• C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
• C07D 209/12 - Radicals substituted by oxygen atoms
• C08G 69/42 - Polyamides containing atoms other than carbon, hydrogen, oxygen, and nitrogen

Abstract

A method for computing a shared key (K) for encrypting data between a first device and a second device. The method includes communicating a first private ephemeral key (XA), and a first parameter set (YA) to a second device. The first parameter set (YA) includes identity data (IDA) that identifies the first device, a random point (VA) on an elliptic curve, and a first public key (UA). The first device receives a second private ephemeral key (XB) and a second parameter set (YB). The second parameter set (YB) includes identity data (IDB) that identifies the second device, a random point (VB) on the elliptic curve, and a second public key (UB). Verifying operations are performed to verify the second public key (UB) and the second private ephemeral key (XB) as valid. A shared key (K) is then computed based at least on the first parameter set (YA), the second parameter set (YB), the first private ephemeral key (XA), and the second private ephemeral key (XB).

IPC Classes  ?

• H04L 9/08 - Key distribution
• H04L 9/30 - Public key, i.e. encryption algorithm being computationally infeasible to invert and users' encryption keys not requiring secrecy
• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules

Abstract

The present invention describes a recombinant antigen derived from the non-structural protein 1 of ZIKV ((ΔN-NS1) capable of specifically differentiating antibodies generated after infection with ZIKV from antibodies generated after infection with dengue virus (DENV) or other flaviviruses. In addition, the present invention describes the assembly of sorological diagnostic kits for detecting ZIKV on different technological platforms, and its use for the differential diagnosis of ZIKV-infected individuals.

IPC Classes  ?

• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• C12N 15/49 - Lentiviridae, e.g. immunodeficiency viruses such as HIV, visna-maedi virus, equine infectious anaemia virus
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• A61K 39/12 - Viral antigens
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

IPC Classes  ?

• A61K 31/055 - Phenols the aromatic ring being substituted by halogen
• C07C 69/63 - Halogen-containing esters of saturated acids
• C07C 39/42 - Halogenated derivatives containing six-membered aromatic rings and other rings
• C07C 69/16 - Acetic acid esters of dihydroxylic compounds
• C07C 39/373 - Halogenated derivatives with all hydroxy groups on non-condensed rings and with unsaturation outside the aromatic rings

Abstract

The present invention relates to a method for producing hybrid or non-hybrid recombinant glycoprotein hormones, for example the recombinant equine chorionic gonadotropin (r-eCG), the hybrid recombinant chorionic gonadotropin, the recombinant thyroid-stimulating hormone (r-TSH), the recombinant luteinising hormone (r-LH), the luteinising hormone and the recombinant follicle-stimulating hormone (r-FSH). In addition, the present invention relates to the recombinant glycoprotein hormones comprising the equine α and β subunits, inter alia, the α subunit of mammals and equine β subunit, where the two subunits are fused in a simple chain, and chain-modifying agents, which hormones are easier to purify, more homogeneous, easier to produce on an industrial scale without using animals, in comparison with the wild glycoprotein hormone. Moreover, the present invention relates to the use of these hormones in assisted animal reproduction, ovulation induction, superovulation induction, follicle growth, oestrus induction, anoestrus reversal, puberty induction in animals, both with and without commercial interest.

IPC Classes  ?

• C07K 14/59 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. hCG [human chorionic gonadotropin]Luteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• C12N 15/16 - Hormones
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• A61K 38/24 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. HCGLuteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
• G01N 33/76 - Human chorionic gonadotropin
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

IPC Classes  ?

• A61K 31/055 - Phenols the aromatic ring being substituted by halogen
• C07C 39/42 - Halogenated derivatives containing six-membered aromatic rings and other rings
• C07C 69/63 - Halogen-containing esters of saturated acids

Abstract

The present invention relates to the production of a recombinant equine chorionic gonadotropin (reCG), to a veterinary composition containing said reCG, and to the use of said reCG or of the composition containing said reCG. The reCG of the present invention has a glycosylation profile similar to that of commercially available chorionic gonadotropins and exhibits an in vivo activity level corresponding to that of eCG and similar to that of the hormones FSH and LH. The present invention is applicable in the field of biotechnology, and more particularly in the field of veterinary assisted reproduction, being especially suitable for use in treating veterinary conditions related to reproduction and ovulation in mammals, and for producing diagnostic kits or as a cell culture supplement.

IPC Classes  ?

• A61K 38/24 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. HCGLuteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• C12N 15/16 - Hormones
• C07K 14/59 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. hCG [human chorionic gonadotropin]Luteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/53 - Oxidoreductases (1)
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

An apparatus (1) for dressing a grinding wheel (2) mounted thereon by creating structures (12) on the surface of a, in particular cylindrical, grinding surface (3) of the grinding wheel (2), the apparatus (1) comprising: - a dressing tool holder (6) arranged for accommodating a dressing tool (4) in a dressing position, - a controllable actuator (7) for adjusting the position of the tool holder (6) within the apparatus (1) in at least one direction (x), - a grinding wheel support (14) for rotatably supporting a grinding wheel (2) to be dressed, the apparatus (1) further comprises means (13, 9) for monitoring an individual structure (12), created by the dressing tool (4) on the surface of the grinding wheel (2), and means (8) for monitoring a circumferential position and/or the rotary speed (19) of the grinding wheel (2), and means (10) for controlling the actuator (7), adapted to control the actuator (7) as a function of the monitored structure (12) and the monitored circumferential position and/or rotary speed (19).

IPC Classes  ?

• B24B 53/00 - Devices or means for dressing or conditioning abrasive surfaces
• B24B 53/04 - Devices or means for dressing or conditioning abrasive surfaces of cylindrical or conical surfaces on abrasive tools or wheels
• B24B 53/08 - Devices or means for dressing or conditioning abrasive surfaces of profiled abrasive wheels controlled by information means, e.g. patterns, templets, punched tapes or the like
• B24B 49/00 - Measuring or gauging equipment for controlling the feed movement of the grinding tool or workArrangements of indicating or measuring equipment, e.g. for indicating the start of the grinding operation

Abstract

The present invention describes an oral pharmaceutical composition containing cannabinoid(s), an oily liquid solvent and a co-solvent, and a method for preparing and using same for the treatment of neurological disorders, especially refractory epilepsy. The analytical methods used to ensure the authenticity, quality and purity of the active pharmaceutical input and of the formulation produced were validated and have defined specifications.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/20 - HypnoticsSedatives

Abstract

The invention refers to an detector for detecting electromagnetic radiation with a high sensitivity. The detector is comprising a substrate (3), a conducting layer (1) which is confining a two-dimensional charge carrier gas, a dielectric layer (4) lying on the conducting layer, at least two electric contacts (2a, 2b) being electrically connected with the conducting layer and at least one top gate contact (5) covering a part of the dielectric layer, wherein the top gate contact is comprising a first section (5 a) and a second section (5b) which are connected with each other by a bridge section (5 c) having a minimum width (d) smaller than the width (D) of the first and second sections. The bridge section thereby is forming a constricted portion of the top gate contact, which is defining a quantum point contact (QPC) in the conducting layer when the top gate contact is electrically biased with respect to the conducting layer.

IPC Classes  ?

• H01L 31/101 - Devices sensitive to infrared, visible or ultraviolet radiation

Abstract

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

IPC Classes  ?

• A61K 31/025 - Halogenated hydrocarbons carbocyclic
• A61K 31/03 - Halogenated hydrocarbons carbocyclic aromatic
• A61K 31/035 - Halogenated hydrocarbons having aliphatic unsaturation
• C07C 22/02 - Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
• C07C 25/13 - Monocyclic aromatic halogenated hydrocarbons containing fluorine

Abstract

This invention describes the development of technology for the preparation of superparamagnetic lipophilic nanofluids, as well as of drilling fluid additives based on the aforementioned nanofluids, which improve the properties which form walls or mud filter cakes and concomitantly act as contrast agents in RMN logging.

IPC Classes  ?

• C01G 49/08 - Ferroso-ferric oxide [Fe3O4]
• C09K 8/58 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids
• C09K 8/035 - Organic additives

Abstract

The present invention describes composite materials presenting an optical, electrical or optoelectronic response to stimuli, respective production method and application as sensitive films for the detection or quantification of a variety of analytes and analyte patterns, including but not limited to volatile organic compounds (VOC), vapors and gases, biomolecules, microorganisms, viruses, cells, and particles, as well as differences of temperature, pressure and electromagnetic fields. The composite material contains a mixture of (i) at least one liquid crystal; (ii) at least one ionic liquid or molecules with surfactant properties; (iii) polymer (s), preferably with natural or synthetic origin; (iv) appropriate solvent (s); optionally (v) a stabilizing element, such as sorbitol; and (vi) an electrolyte, which can be dispensed when the sensitive film is used to obtain an exclusively optical response or when the ionic liquid (s) or surfactant ( s ) are also conducting materials.

IPC Classes  ?

• C09K 19/52 - Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives

Abstract

The present application defines a method for producing urea-based nitrogenated fertilizer, comprising the preliminary micronization of urea (to particles of less than 10 μn), and subsequent addition of an urease inhibitor (H3BO3, CuSO4 or N-(n-butyl)thiophosphoric triamide (NBPT)) and/or a clay mineral (zeolite), followed by granulation. The application also relates to the thus obtained fertilizer in the form of a granulate, pellets or tablets.

IPC Classes  ?

• C05C 9/00 - Fertilisers containing urea or urea compounds
• C05G 3/08 - Mixtures of one or more fertilisers with materials not having a specifically fertilising activity with agents affecting the nitrification of ammonium compounds or urea in the soil
• C05G 3/10 - Mixtures of one or more fertilisers with materials not having a specifically fertilising activity with dust-preventing coatings
• B01J 2/02 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops

Abstract

The present invention describes the method for obtaining an ethanol extract from endocarp-enclosed seeds (pits) of the avocado fruit (Persea americana), the hexane, dichloromethane, ethyl acetate and hydro-alcoholic fractions of which are incorporated in insecticide compositions for controlling and/or combatting insects. These compositions exhibit thermal stability and solubility at different pH values (from 2 to 12), allowing them to be applied in areas with acid and basic soils. In addition, the invention provides the use of these compositions by means of baits, by incorporation into foodstuffs and by spraying.

IPC Classes  ?

• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01P 7/04 - Insecticides

Abstract

The presence of the human T-cell lymphotropic virus (HTLV) can be detected and virus type I or II can be identified by the present method, which involves the amplification of DNA sequences of HTLV by real-time polymerase chain reaction. For that purpose, primers were developed to amplify a particular region of the genome of HTLV-I and HTLV-II. The presence of HTLV-I and/or HTLV-II in a sample is indicated by the fluorescence released by probes specific to each subtype.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/33 - Genes encoding viral proteins

Abstract

The present invention relates to synthetic peptides that bind to VEGF tyrosine kinase receptors and uses thereof. Said peptides can be used, separately or in combination, for preventing or treating diseases in which VEGF receptors play an important role in the initiation and progression of the pathology, such as diseases with an angiogenic component.

IPC Classes  ?

• C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans
• A61K 38/03 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof

Abstract

4 associated to an activated charcoal adsorbent substrate, a process to obtain and methods of use of the nanocomposite. The present invention enables the processing, concentration and recovery of large volumes of contaminated water, regenerating magnetic adsorbent material for reuse, in a cyclic and sustainable manner, transforming dispersed/diluted pollutants in pre-concentrates that can be easily processed, helping to conserve natural resources.

IPC Classes  ?

• B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
• B03C 1/01 - Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
• B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
• C02F 1/28 - Treatment of water, waste water, or sewage by sorption
• C02F 101/30 - Organic compounds
• C02F 103/30 - Nature of the water, waste water, sewage or sludge to be treated from the textile industry
• C02F 103/28 - Nature of the water, waste water, sewage or sludge to be treated from the processing of plants or parts thereof from the paper or cellulose industry
• C02F 101/20 - Heavy metals or heavy metal compounds
• C02F 103/36 - Nature of the water, waste water, sewage or sludge to be treated from the chemical industry not provided for in groups from the manufacture of organic compounds
• C02F 1/48 - Treatment of water, waste water, or sewage with magnetic or electric fields

Abstract

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

IPC Classes  ?

• A61K 31/055 - Phenols the aromatic ring being substituted by halogen
• C07C 39/42 - Halogenated derivatives containing six-membered aromatic rings and other rings
• C07C 69/63 - Halogen-containing esters of saturated acids
• C07C 69/16 - Acetic acid esters of dihydroxylic compounds
• C07C 39/373 - Halogenated derivatives with all hydroxy groups on non-condensed rings and with unsaturation outside the aromatic rings

Abstract

The present invention pertains to the electric energy industry, more specifically to an ethanol dehydrogenation system which converts ethanol into a more energy-rich fuel for use in combustion engines, at the same time as producing hydrogen without carbon monoxide, which is led to a fuel cell for producing electric energy for the subsequent electric and/or hybrid propulsion of motor vehicles. The present invention preferably relates to a method for producing energy in a hybrid vehicle, comprising the following steps: (a) providing a catalytic reactor (5); (b) feeding the catalytic reactor (5) with a stream of evaporated fuel; (c) leading the evaporated reagents to the catalytic reactor (5); (d) performing liquid fuel dehydrogenation reactions in the catalytic reactor (5); (e) cooling the output stream so as to separate the gaseous stream (9) from the liquid fuel stream; (f) supplying the liquid stream to an internal combustion engine (8) to generate energy, or returning the liquid stream to the catalytic reactor (5); (g) capturing an air stream (11); and (h) leading the gaseous stream (9) to the anode of the fuel cell (10) and the air stream (11) to the cathode of the fuel cell (10) to generate electric energy. In addition, the present invention describes a system for producing energy in a hybrid vehicle and a hybrid vehicle which use this method.

IPC Classes  ?

• B01J 8/02 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with stationary particles, e.g. in fixed beds
• C01B 3/32 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air
• H01M 8/06 - Combination of fuel cells with means for production of reactants or for treatment of residues
• B01J 23/72 - Copper
• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof

Abstract

The present invention relates to a method for selecting tick antigens, comprising the following steps: producing a tick transcriptome; synthetising the proteins; selecting the antigenic proteins; assessing the biological importance of the selected proteins; cloning and subcloning the DNA sequences relating to the selected proteins; synthetising antigens against ticks; and also, to antigenic compositions against ticks useful for mammals.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/12 - Genes encoding animal proteins
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 33/14 - Ectoparasiticides, e.g. scabicides

Abstract

The instant disclosure describes a radiofrequency propagation line including a conducting strip connected to a conducting plane parallel to the plane of the conducting strip, wherein the conducting plane includes a network of nanowires made of an electrically conductive, non-magnetic material extending orthogonally to the plane of the conducting strip, in the direction of said conducting strip.

IPC Classes  ?

• H01P 9/00 - Delay lines of the waveguide type
• H01P 3/00 - WaveguidesTransmission lines of the waveguide type
• H01P 3/08 - MicrostripsStrip lines

Abstract

The present invention relates to the chemically modified polynucleotides of formula (I): 5'- CONS-SEQ.ID.n-CONS-3' (I) containing one or more modified pyrimidines and at least one inverted nucleotide repeat; and to the method for producing the same.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• G01N 33/5 -
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

The present invention refers to methods for production and/or purification of hormones, particularly follicle stimulating hormone (FSH), from human or animal origin, using a human cells platform, as well as products thus obtained and their uses.

IPC Classes  ?

• C12N 15/18 - Growth hormones
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C07K 14/59 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. hCG [human chorionic gonadotropin]Luteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• C07K 1/16 - ExtractionSeparationPurification by chromatography
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

The present invention relates to pharmaceutical compositions comprising a peptide that stimulates the release of gonadotropins and sexual steroids. More specifically, the present invention proposes pharmaceutical compositions comprising kisspeptin, preferably in the kp-10 form, or derivatives thereof, for use in ovulation cycle inducing and/or infertility treatment programs. The formulations according to the present invention belong to two main groups: injectable solutions and implantable formulations. The injectable solutions according to the present invention can be divided into immediate release solutions and prolonged action solutions. The implantable formulations according to the present invention can be prepared using an RTV silicone elastomer, a rapid vulcanisation silicone elastomer or a rapid vulcanisation silicone elastomer with a release modulator.

IPC Classes  ?

• A61K 38/09 - Luteinising hormone-releasing hormone [LHRH]Related peptides
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 9/107 - Emulsions
• A61K 9/22 - Sustained or differential release type
• A61D 19/00 - Instruments or methods for reproduction or fertilisation
• A61P 5/22 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin

Abstract

The present invention relates to an electrochromic device (ECD) with a structure having five types of layers: a substrate (1), an electronic conductor (2), a primary electrochromic layer (3), an ion conductor (4) and an ion storage layer and/or complementary electrochromic layer (5). The invention also relates to the use of said device. The electrochromic device preferably has two main colours: green and yellow, depending on the colour combination seen through the layers. The present invention relates to two types of use of the electrochromic device, the first type consisting of a single pixel, among a plurality of pixels, and the second type relating to a single device used as an electrochromic window.

IPC Classes  ?

• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
• G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect
• G02F 1/153 - Constructional details

Abstract

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

IPC Classes  ?

• C07C 69/16 - Acetic acid esters of dihydroxylic compounds
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

IPC Classes  ?

• C07C 69/16 - Acetic acid esters of dihydroxylic compounds
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 35/00 - Antineoplastic agents
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Nanofibres with an active substance for cosmetic application, containing nitrogenated organic compounds of the xanthine (caffeine) group, these nanofibres being produced by electrospinning using polymer solutions in the presence of the active ingredient, in order to achieve its encapsulation and subsequent controlled release in an area of the skin, preferably to combat cellulite (gynoid hydrolipodystrophy - GHLD).

IPC Classes  ?

• A61K 8/00 - Cosmetics or similar toiletry preparations
• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• B82B 1/00 - Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

Additives are described for use in epoxy-based anti-corrosive coatings with high solid content, in liquid form, comprising microcapsules that contain a regenerating agent dispersed in an organic diluent. The coatings to which this dispersion is added can self-regenerate in the event of damage (cracks or scratches) to the coating applied to and cured on the metal surface, thus preventing corrosion of the exposed metal surface from propagating.

IPC Classes  ?

• C09D 7/12 - Other additives
• C09D 5/08 - Anti-corrosive paints
• C09D 163/00 - Coating compositions based on epoxy resinsCoating compositions based on derivatives of epoxy resins

Abstract

The present invention relates to a method for increasing embryo implantation rate in mother's uterus in mammals by administering to the uterus of a mammal an effective amount of beta-galactoside-binding lectin or derivatives thereof, as well as to a product comprising said lectin.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention concerns rapid alkalization factors peptides (RALF peptides) that can be used for delivering nucleic acids to both plant and animal cells, in vivo or in vitro. Also provided are methods for introducing a molecule of interest into a plant or animal cell using RALF peptides for genetically modifying them, and kit s comprising said RALF peptides.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The present invention relates to the identification of a novel biomarker for cardiac ischemia: nitrated cardiac troponin I. The present invention also provides methods for the identification and use of a nitrated cardiac troponin as a biomarker for the diagnosis, prognosis and treatment management of myocardial ischemia, with and without necrosis of heart muscle. Diagnosis and prognosis is conducted by determining the amount of nitrated cardiac troponin I in serum samples of subjects and the ratio of nitrated cardiac troponin I to non-nitrated cardiac troponin I in serum samples of subjects. This biomarker can be detected by immunoassay techniques and tandem mass spectrometry. The present invention further relates to peptides, antibodies, compositions, methods, techniques, tests and kits for the identification and quantification of nitrated cardiac troponin I in samples of subjects.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

The present invention relates to the construction and insertion of a DNA plasmid vector of broad spectrum for Gram-negative bacteria, that carries a gene sequence which, when expressed, enables the anchorage of a chelating protein for arsenic ions on the Gram-negative bacteria cellular surface. For that end, the structural sequence of the regulatory arsR gene without stop codon (SEQ ID N° 1 ) was amplified by Polymerase Chain Reaction (PCR) using as a template the chromosome 1 of Cupriavidus metallidurans, CH34 lineage and inserted into the pGEM-T cloning vector, yielding the pGEMT-As plasmid (SEQ ID N° 2). The expression vector containing the sequence encoding the cassette for the expression and anchoring of heterologous proteins in Gram-negative bacteria, under the control of the pan promoter (SEQ. ID N° 3), was obtained upon digestion of the pCM-Hg plasmid with Xbal and Sa/I restriction enzymes. The arsR gene was released from the pGEMT-As plasmid by digestion with Xba\ and Sa/I restriction enzymes and then ligated to the linearized expression vector, called pCM (SEQ. ID N° 4), resulting in the construction of the pCM-As plasmid (SEQ ID N° 5). Additionally, the present invention provides recombinant strains of Gram-negative bacteria containing said recombinant plasmid, method of production, use of the recombinant plasmid to enhance bacterial arsenic resistance and capability to adsorb arsenic ions, as well as the use of the transgenic strains for the adsorption of arsenic ions in environmental bioremediation processes, with the possibility of recovering the metalloid as a byproduct.

IPC Classes  ?

• C07K 14/225 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Alcaligenes (G)

Abstract

The invention relates to a radiofrequency propagation line including a conducting strip (31) connected to a conducting plane (37) parallel to the plane of the conducting strip, wherein the conducting plane includes a network of nanowires (36) made of an electrically conductive, non-magnetic material extending orthogonally to the plane of the conducting strip, in the direction of said conducting strip.

IPC Classes  ?

• H01P 3/00 - WaveguidesTransmission lines of the waveguide type
• H01P 3/08 - MicrostripsStrip lines

Abstract

The invention provides P. vivax vaccine compositions.

IPC Classes  ?

• A61K 39/002 - Protozoa antigens
• A61P 33/06 - Antimalarials
• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens

Abstract

The present invention discloses the use of the bacterial cellulose membrane in ligament, tendon and synovial capsule reconstructions according to the methods described in the technical description of the invention. Said material could be used in the reconstruction of ligaments and tendons (the knee cruciate ligaments, patellar ligament, Achilles tendon, quadriceps tendon, etc.) and the synovial capsule.

IPC Classes  ?

• A61L 27/20 - Polysaccharides
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/56 - Porous or cellular materials
• A61L 27/58 - Materials at least partially resorbable by the body
• A61L 27/24 - Collagen
• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/14 - Materials characterised by their function or physical properties
• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61K 35/14 - BloodArtificial blood
• A61K 31/728 - Hyaluronic acid

Abstract

The present invention relates to the construction and insertion of a wide spectrum vector for Gram-negative bacteria, having a gene sequence which, when expressed, allows a mercury ion chelating protein to be anchored onto the cell surface of gram-negative bacteria. For that purpose the merR regulatory gene was isolated from the pMOL30 plasmid of Cupriavidus metallidurans, line CH34 (SEQ ID NO. 1) and inserted into the pGEMT cloning vector, producing the PGEMT-Hg plasmid (SEQ ID NO. 2). The expression vector containing the sequence corresponding to the cassette for expressing and anchoring heterologous proteins in Gram-negative bacteria under the control of the pan promoter (SEQ ID NO. 3) derived from the pCM2 plasmid was obtained by polymerase chain reaction (PCT). The merR gene was merged with the amplified expression vector, leading to the construction of the pCMHg plasmid (SEQ ID NO. 4). In addition, the present application provides mutant strains of Gram-negative bacteria containing said recombinant plasmid, a method of obtaining same, and discloses the possible use of the transgenic strain for adsorbing mercury ions in environmental bioremediation processes.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material

Abstract

The present invention relates to a cosmetic composition for topical application and containing spirulina, with the main objective of combating the action of free radicals that affect ageing, besides moisturising, protecting and improving the general skin condition. The composition contains spirulina in the form of a dry extract in concentrations ranging from 0.1 to 5.0% by weight, and cosmetically acceptable carriers.

IPC Classes  ?

• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61K 8/06 - Emulsions
• A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
• A61Q 19/08 - Anti-ageing preparations

Abstract

The object of the present invention is to provide methods for the production of recombinant human Factor VIII, employing specific endoproteases, thus assuring full proteolytic processing of said factor even during its biosynthesis, consequently avoiding additional purification steps. Other objects of the present invention are the recombinant human Factor VIII as obtained by said methods, pharmaceutical compositions, related uses and therapeutic methods.

IPC Classes  ?

• C07K 14/755 - Factors VIII
• C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

The present invention relates to: 1) the method for producing recombinant FVIII in the human cell Sk-Hep-1, comprising the Von Willebrand Factor (vWF) and 2) the population of human cells transfected with a vector encoding the coagulation protein (FVIII). The technique, which is the object of the present patent application, relates to cultivating the human cells in suspension and adhered, and isolating the culture medium containing the desired protein. The aim of the invention is to produce a more secure (free of potential human viruses), more stable and cheaper product, and by means of a process that produces sufficient quantities of said product, on an industrial scale, for fulfilling national requirements.

IPC Classes  ?

• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/07 - Animal cells or tissues

Abstract

The present invention relates to a method for increasing embryo implantation rate in mother's uterus in mammals by administering to the uterus of a mammal an effective amount of beta-galactoside-binding lectin or derivatives thereof, as well as to a product comprising said lectin.

IPC Classes  ?

• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

Plants are influenced by a large number of biotic and abiotic environmental factors, recurrent abiotic stresses being the most serious and affecting all organic functions of the plants, leading to reduced growth and productivity. In this context, identifying and understanding abiotic resistance mechanisms are crucial for developing new drought-resistant cultivars. The present invention thus provides a method for producing plants containing in their cells a sugarcane nucleotide sequence, overexpression of this gene increasing the plant's resistance to abiotic stresses. More generally, a polynucleotide is described that encodes sugarcane protein and is expressed by a promoter and a terminator that are operational in plants. This gene has been discovered to impart resistance to various abiotic stresses.

IPC Classes  ?

• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/14 - Plant cells

Abstract

Plants are influenced by a large number of biotic and abiotic environmental factors, recurrent abiotic stresses being the most serious and affecting all organic functions of the plants, leading to reduced growth and productivity. In this context, identifying and understanding abiotic resistance mechanisms are crucial for developing new drought-resistant cultivars. The present invention thus provides a method for producing plants containing in their cells a sugarcane nucleotide sequence, overexpression of this gene increasing the plant's resistance to abiotic stresses. More generally, a polynucleotide is described that encodes sugarcane protein and is expressed by a promoter and a terminator that are operational in plants. This gene has been discovered to impart resistance to various abiotic stresses.

IPC Classes  ?

• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/14 - Human serum albumins

Abstract

The present innovation relates to the identification of the main sequences of the protein nucleoside hydrolase from Leishmania (L) donovani, to be included in a recombinant, DNA or synthetic vaccine to protect and cross-protect against leishmanioses. It also relates to the identification of the main epitopes that react with antibodies to be used in the immunodiagnosis of leishmanioses, and to the use thereof to give cross-protection against other micro-organisms having a sequence in common in the nucleoside hydrolases thereof.

IPC Classes  ?

• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• C12N 9/14 - Hydrolases (3.)
• C12N 15/55 - Hydrolases (3)
• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• A61K 39/008 - Leishmania antigens
• A61P 33/00 - Antiparasitic agents
• C12R 1/90 - Protozoa

Abstract

The invention application presents a fast, efficient, reproductive alternative of a non-invasive method for diagnosing the severity of heart failure based on a specific biomarker. An additional object of the present inven- tion is a collector device for the biomarker from exhaled breath that is portable, simple, low cost and does not need to run on electric power. This invention advantageously permits the replacement of invasive diagnosis methods, favoring the patient's comfort in addition to the agility and speed of medical attention at hospitals, and may become a standard method for all suspected cases of circulatory disease and heart failure and, more specifically, decompensated heart failure.

IPC Classes  ?

• A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices

Abstract

The invention "colloidal nanoscale carriers for active hydrophilic substances and method for producing same" pertains to the field of medical, odontological or hygiene preparations, and is characterised by structures formed by hydrophilic polymers that contain active hydrophilic substances coated with a non-hydrophilic phase and surfactants with affinity for the components, forming an invert emulsion that allows the incorporation and controlled delivery of active hydrophilic substances, conferring properties such as protection against degradation processes, improvement of compatibility with the other components of the formulation in the final product, increase in the availability and/or bioavailability of the active substance in the medium of interest (including improvements in permeation processes in biological materials, reduction of the exposure and volatilisation of the active substance in the medium) and controlled release of the active substance(s). The nanoscale carrier obtained by this method, called colloidal nanoscale carrier (NC), can be used in various fields, such as the pharmaceutical field (including dermatology), cosmetics, personal hygiene products, veterinary medicine, agrochemicals and fertilizers, the food industry and the like. The invention proposes a kinetically stable system with an effective nanoscale structure that consists of nanoscale carriers formed by polymers emulsified in a non-aqueous medium in the presence of a surfactant with affinity for the two phases (the dispersion medium and the encapsulating agent). This system is obtained by nanoemulsification of an aqueous phase of hydrophilic polymers emulsified in a non-hydrophilic (lipophilic or silophilic) phase that contains the surfactants, and is characterised by the implementation of two concepts that encompass the generation of an invert nanoscale emulsion and of polymer nanoparticles. The formulation has the novel technical effect of providing a polymer excipient with a nanoscale structure for delivering hydrophilic molecules suspended in a non-hydrophilic phase, which allows controlling the size of the nanoscale particles and modulating colloidal stability by means of process parameters.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

The invention relates to the production of bone grafts or scaffolds from suspensions based on a bioactive glass-ceramic, Biosilicate®, composed of Na2O-CaO-SiO2-P2O5. The suspensions containing Biosilicate® powder are processed in various ways (direct foaming, rapid prototyping or polymer sponge method) to produce the scaffold (graft or prosthesis) having the suitable shape for achieving the desired bone regeneration. The scaffolds produced using Biosilicate® and the present method achieve a porosity from 65-95% and an average pore size from 100-600μm, when the suspensions are obtained by adding a pore-forming material. The scaffolds obtained by the polymer sponge method have a structure similar to that of trabecular bone, with interconnected pores of 100-200μm and a total porosity from 70-98%. The finished prosthesis consists of a bioactive and resorbable material with excellent bone induction and bone conduction, with a structure of interconnected pores that retains suitable mechanical properties. In view of these features, the thus produced scaffold or prosthesis is an excellent alternative for bone grafts used in odontological, orthopedic, maxillofacial, craniofacial surgery, in cases of bone neoplasia and to stabilise segments of the vertebral column. In this context, the present application seeks protection for: Biosilicate® suspensions used to produce bone grafts, the method for producing these grafts and the various scaffolds (bone grafts) produced by this method.

IPC Classes  ?

• A61F 2/28 - Bones
• A61L 27/00 - Materials for prostheses or for coating prostheses
• A61L 27/10 - Ceramics or glasses
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 27/56 - Porous or cellular materials
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

The present invention relates to a method for preparing matrix micro-particles of Copaífera langsdorffii (aerial parts) and for isolating the active compounds and/or markers of the aerial parts of said plant, as well as the biological activities which these matrix micro-particles and isolated compounds have been discovered to have, that is: anti-lithiasis activity (renal calculi), analgesic, anti-spasmodic, anti-inflammatory, diuretic and antiseptic activities. Also disclosed is the use thereof for the treatment of renal lithiasis (renal calculi), arthritis, tartar, muscle and spasmodic pain in general (abdominal and renal colics, etc.). The present invention also relates to other diseases associated with the previously mentioned activities, and to the formulations that can be produced with the matrix micro-particles of Copaífera langsdorffii, and/or to the isolated compounds, used as medicaments, personal hygiene products, cosmetics, nutritional, veterinary and odontological products, inter alia.

IPC Classes  ?

• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61K 127/00 - Containing or obtained from leaves
• A61P 13/04 - Drugs for disorders of the urinary system for urolithiasis
• A61P 13/06 - Anti-spasmodics
• A61P 7/10 - Antioedematous agentsDiuretics

Abstract

The present invention refers to a human blood coagulation factor IX recombinant protein and a composition containing it. The present invention also deals with the use of the protein or composition of the invention for the manufacture of a medicine to treat hemophilia B. Additionally, the present invention refers to the method of obtaining a human blood coagulation factor IX mutated recombinant protein. Another object of the present invention is the mutated recombinant protein obtained by the method described herein, and its use in order to prepare a medicine for the treatment of hemophilia B.

IPC Classes  ?

• C07K 14/745 - Blood coagulation or fibrinolysis factors

Abstract

The invention concerns cosmetic and/or pharmaceutical formulations containing an extract of Ilex paraguariensis (yerba mate), particularly photoprotectors (sun filters) with wide spectrum (UVA and UVB protection) sun protection factor (SPF) and, optionally, a synthetic stabilizer and/or organic and/or inorganic synthetic sun filters.

IPC Classes  ?

• A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations

Abstract

The present invention relates to the use of serpentine receptors existent in parasites of genus Plasmodium for treating malaria.

IPC Classes  ?

• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 33/06 - Determining fat content, e.g. by butyrometer

Abstract

Process of obtaining of standardized extracts, fractions and isolated substances of propolis or baccharis species, formulations of standardized extracts, fractions and isolated substances of propolis or baccharis species, and the use of formulations of standardized extracts, fractions and isolated substances of propolis or baccharis species as sanitizer, antiseptic and/or disinfecting products for microbiological control, in fixed surfaces, alimentary and similar industries, dairy products, not critical, semi-critical and critical goods, as well as in the antisepsis of hands and skin.

IPC Classes  ?

• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea

Abstract

This invention provides a product for therapy and vaccination, constituted by a functional liposomal configuration containing complexed polynucleotides preferably on the outer surface of dehydrated-rehydrated liposomes (DRV), and the production process thereof. This functional liposomal configuration containing polynucleotides has mucoadhesion properties which allow administration by non-invasive routes, such as the nasal route, and is able to efficiently carry the polynucleotides to the interior of cells, releasing them in the cytoplasm. These properties allows for higher in vivo action efficiency of the carried polynucleotides, reduced concentration and dose frequency, and, in the case of vaccination, give protection against the specific disease. The present technology also develops a liposomal configuration carrying polynucleotides, which encode the protein HSP65, for prevention and treatment of tuberculosis.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

A multilayer microdevice containing microchannels and having integrated electrodes and its preparation process. In a preferred embodiment, the microchannels are made made from toner. Planar electrodes are fabricated using toner masks by the steps of: covering the substrate with photosensitive material, photoengraving the desired image, developing, sputtering deposition onto substrates, and removal of toner layer by a lift-off process.

IPC Classes  ?

• G01N 27/447 - Systems using electrophoresis
• G01N 27/453 - Cells therefor

Abstract

The invention relates to the identification of astrocytoma markers, astrocytoma stem cells and markers of such stem cells, and diagnostic, prognostic and therapeutic methods based on an understanding of the markers and cells.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention provides an equipment and a process to increase muscular resistance or reduce muscular fatigue, both based on the application of Low Level LASER with a wavelength operating in the visible to infrared range that, in a controlled manner, modulates the capacity of muscular resistance to fatigue and the concentration of post-exercise blood lactate. The equipment and process are, therefore, useful in various medical/sporting applications such as, for example: athletic performance and post-exercise recovery; chronic back pain; neck pain; fibromialgia; all and any illness involving muscular fatigue and the local reduction of the blood flow to the muscular tissue. The equipment and process of the invention also provide a post-exercise reduction of the levels of creatine kinase and lactate.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light